0.89
price up icon1.14%   0.01
after-market Dopo l'orario di chiusura: .85 -0.04 -4.49%
loading
Precedente Chiudi:
$0.88
Aprire:
$0.9
Volume 24 ore:
48,461
Relative Volume:
0.42
Capitalizzazione di mercato:
$21.08M
Reddito:
-
Utile/perdita netta:
$-22.29M
Rapporto P/E:
-0.7542
EPS:
-1.18
Flusso di cassa netto:
$-17.12M
1 W Prestazione:
-0.17%
1M Prestazione:
-14.83%
6M Prestazione:
-39.46%
1 anno Prestazione:
-29.92%
Intervallo 1D:
Value
$0.88
$0.918
Intervallo di 1 settimana:
Value
$0.84
$0.918
Portata 52W:
Value
$0.8101
$1.84

Enlivex Therapeutics Ltd Stock (ENLV) Company Profile

Name
Nome
Enlivex Therapeutics Ltd
Name
Telefono
-
Name
Indirizzo
-
Name
Dipendente
49
Name
Cinguettio
@EnlivexT
Name
Prossima data di guadagno
2024-09-09
Name
Ultimi documenti SEC
Name
ENLV's Discussions on Twitter

Confronta ENLV con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
ENLV
Enlivex Therapeutics Ltd
0.89 21.08M 0 -22.29M -17.12M -1.18
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
490.47 128.67B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
585.49 60.99B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
599.87 36.96B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
236.75 29.89B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
252.77 25.74B 3.81B -644.79M -669.77M -6.24

Enlivex Therapeutics Ltd Stock (ENLV) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2021-03-02 Reiterato H.C. Wainwright Buy

Enlivex Therapeutics Ltd Borsa (ENLV) Ultime notizie

pulisher
06:17 AM

Enlivex enrols all patients in Phase II stage of knee osteoarthritis trial - Yahoo Finance

06:17 AM
pulisher
01:57 AM

Enlivex Therapeutics (NASDAQ:ENLV) Given “Buy” Rating at D. Boral Capital - Defense World

01:57 AM
pulisher
Apr 21, 2025

Enlivex (ENLV) Completes Patient Enrollment for Phase II Allocetra Trial | ENLV Stock News - GuruFocus

Apr 21, 2025
pulisher
Apr 21, 2025

Enlivex Completes Phase II Enrollment for Osteoarthritis Trial - TipRanks

Apr 21, 2025
pulisher
Apr 21, 2025

Enlivex Announces Completion of Enrollment In The Phase II stage Of Its Phase I/II Trial Evaluating Allocetra In Patients With Moderate To Severe Knee Osteoarthritis | ENLV Stock News - GuruFocus

Apr 21, 2025
pulisher
Apr 21, 2025

Enlivex Therapeutics Completes Patient Enrollment in Phase II Trial of Allocetra™ for Knee Osteoarthritis - Nasdaq

Apr 21, 2025
pulisher
Apr 21, 2025

Major Milestone: 133-Patient Phase II Trial Completed for Revolutionary Knee Osteoarthritis Treatment Allocetra - Stock Titan

Apr 21, 2025
pulisher
Apr 07, 2025

Is Enlivex Therapeutics (NASDAQ:ENLV) In A Good Position To Invest In Growth? - Yahoo Finance

Apr 07, 2025
pulisher
Apr 05, 2025

D. Boral Capital Reaffirms “Buy” Rating for Enlivex Therapeutics (NASDAQ:ENLV) - Defense World

Apr 05, 2025
pulisher
Apr 03, 2025

Enlivex Begins Phase I Trial for TMJ Osteoarthritis Treatment - TipRanks

Apr 03, 2025
pulisher
Apr 03, 2025

Enlivex Announces the Dosing of the First Patient in a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis - The Manila Times

Apr 03, 2025
pulisher
Apr 03, 2025

Groundbreaking TMJ Treatment Trial Begins: Enlivex Targets Major Medical Need - Stock Titan

Apr 03, 2025
pulisher
Mar 31, 2025

Enlivex Therapeutics Releases 2024 Financial Statements - TipRanks

Mar 31, 2025
pulisher
Mar 28, 2025

Enlivex Therapeutics (ENLV) to Release Quarterly Earnings on Friday - Defense World

Mar 28, 2025
pulisher
Mar 27, 2025

HC Wainwright Has Negative Estimate for ENLV FY2025 Earnings - Defense World

Mar 27, 2025
pulisher
Mar 26, 2025

HC Wainwright Forecasts Strong Price Appreciation for Enlivex Therapeutics (NASDAQ:ENLV) Stock - The AM Reporter

Mar 26, 2025
pulisher
Mar 25, 2025

Enlivex Therapeutics (NASDAQ:ENLV) Given New $7.00 Price Target at HC Wainwright - Defense World

Mar 25, 2025
pulisher
Mar 24, 2025

Enlivex stock price target raised to $7 at H.C. Wainwright By Investing.com - Investing.com South Africa

Mar 24, 2025
pulisher
Mar 24, 2025

Enlivex stock price target raised to $7 at H.C. Wainwright - Investing.com India

Mar 24, 2025
pulisher
Mar 17, 2025

Enlivex Secures Chinese Patent Allowance for Osteoarthritis Treatment - TipRanks

Mar 17, 2025
pulisher
Mar 17, 2025

Enlivex Receives Notice of Allowance for Chinese Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis - The Manila Times

Mar 17, 2025
pulisher
Mar 17, 2025

Enlivex Therapeutics Secures Patent Allowance in China for Allocetra™ as Treatment for Osteoarthritis - Nasdaq

Mar 17, 2025
pulisher
Mar 17, 2025

Breakthrough: Enlivex's Arthritis Drug Cuts Pain by 47%, Secures Major China Patent Win - StockTitan

Mar 17, 2025
pulisher
Mar 06, 2025

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Short Interest Update - Defense World

Mar 06, 2025
pulisher
Mar 05, 2025

IOBT To Report Melanoma Trial Data In Q3, NPCE Eyes 15-20% Revenue Growth For 2025, DXR On Watch - RTTNews

Mar 05, 2025
pulisher
Mar 05, 2025

Enlivex Therapeutics Announces Investor Webinar to Discuss Positive Interim Data from Phase I/II Allocetra™ Trial in Knee Osteoarthritis - The Manila Times

Mar 05, 2025
pulisher
Mar 04, 2025

Enlivex Reports Promising Interim Results in Osteoarthritis Trial - TipRanks

Mar 04, 2025
pulisher
Mar 04, 2025

Enlivex Therapeutics Announces Investor Webinar To Discuss Positive Interim Data From Phase I/Ii Allocetra(TM) Trial In Knee Osteoarthritis - Marketscreener.com

Mar 04, 2025
pulisher
Mar 04, 2025

Enlivex Therapeutics Ltd. Hosts Investor Webinar to Discuss Positive Interim Data from Allocetra™ Osteoarthritis Trial - Nasdaq

Mar 04, 2025
pulisher
Mar 04, 2025

Can Enlivex's Allocetra Transform Osteoarthritis Treatment? 47% Pain Reduction Reported - StockTitan

Mar 04, 2025
pulisher
Mar 04, 2025

Enlivex Therapeutics (NASDAQ:ENLV) Given Buy Rating at D. Boral Capital - Defense World

Mar 04, 2025
pulisher
Mar 03, 2025

Enlivex Announces Positive Interim Data From Early Stage Trial For Osteoarthritis Treatment - Nasdaq

Mar 03, 2025
pulisher
Mar 03, 2025

Enlivex Reports Promising Interim Results in Knee Osteoarthritis Trial - TipRanks

Mar 03, 2025
pulisher
Mar 03, 2025

Enlivex Announces Positive Interim DataStatistically Significant 47.0% Durable and Persistent Pain Reduction At Six Months, in Patients with Moderate to Severe Knee Osteoarthritis - The Manila Times

Mar 03, 2025
pulisher
Mar 03, 2025

Enlivex Therapeutics Reports Positive Interim Results in Phase I/II Trial of Allocetra™ for Knee Osteoarthritis - Nasdaq

Mar 03, 2025
pulisher
Mar 03, 2025

Can Enlivex's Osteoarthritis Treatment Disrupt a Multi-Billion Dollar Market? 6-Month Data Impresses - StockTitan

Mar 03, 2025
pulisher
Mar 01, 2025

We're Keeping An Eye On Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn Rate - Simply Wall St

Mar 01, 2025
pulisher
Feb 19, 2025

Enlivex Advances Immunotherapy with Japanese Patent for Osteoarthritis Treatment - PUNE.NEWS

Feb 19, 2025
pulisher
Feb 18, 2025

Enlivex Therapeutics (NASDAQ:ENLV) Hails Positive Trial Results for Allocetra Treatment of Knee Osteoarthritis - Markets Insider

Feb 18, 2025
pulisher
Feb 18, 2025

Enlivex Therapeutics Starts Phase II Allocetra Trail to Treat Knee Osteoarthritis - Markets Insider

Feb 18, 2025
pulisher
Feb 18, 2025

Enlivex Wins Key Patent in Japan for Osteoarthritis Treatment - Markets Insider

Feb 18, 2025
pulisher
Feb 18, 2025

Enlivex Therapeutics Completes Initial Dosing in Phase I Psoriatic Arthritis Trial - Markets Insider

Feb 18, 2025
pulisher
Feb 18, 2025

Enlivex Issues Urgent Statement on Fraudulent News Dissemination - The Manila Times

Feb 18, 2025
pulisher
Feb 18, 2025

Enlivex Therapeutics Denies False Report of Trading Suspension and Reaffirms Business Operations - Nasdaq

Feb 18, 2025
pulisher
Feb 12, 2025

CollPlant Biotechnologies Provides a Corporate Update - Quantisnow

Feb 12, 2025
pulisher
Feb 11, 2025

Tryptamine Therapeutics Appoints New Auditor Amid Global Expansion - TipRanks

Feb 11, 2025
pulisher
Feb 11, 2025

RedChip Announces Webinar to Teach Investors How to Use RedChat, a Revolutionary AI Chatbot for Small-Cap Stock Analysis - Yahoo Finance

Feb 11, 2025
pulisher
Feb 10, 2025

Enlivex Therapeutics’ (ENLV) “Buy” Rating Reiterated at D. Boral Capital - Defense World

Feb 10, 2025
pulisher
Feb 06, 2025

Enlivex Therapeutics (NASDAQ:ENLV) Stock Price Up 1.9% – Time to Buy? - Defense World

Feb 06, 2025
pulisher
Jan 30, 2025

Sepsis Market Forecasted to Surge in Coming Years, 2024-2034 - openPR

Jan 30, 2025
pulisher
Jan 25, 2025

Enlivex Receives Regulatory Authorization From Israel’s Health Ministry For The Initiation Of Phase 1/2 Trial Evaluating Allocetra In Patients With Knee Osteoarthritis - ACCESS Newswire

Jan 25, 2025

Enlivex Therapeutics Ltd Azioni (ENLV) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$20.27
price up icon 1.00%
$71.24
price up icon 2.49%
$32.19
price up icon 0.00%
$27.35
price up icon 8.45%
$104.68
price up icon 2.82%
biotechnology ONC
$252.77
price up icon 10.27%
Capitalizzazione:     |  Volume (24 ore):